Source: European Medicines Agency (EU) Revision Year: 2019 Publisher: Roche Registration GmbH, Emil-Barell-Strasse 1, 79639 Grenzach-Wyhlen, Germany
Cotellic 20 mg film-coated tablets.
Pharmaceutical Form |
---|
Film-coated tablet. White, round film-coated tablets of approximately 6.6 mm diameter, with “COB” debossed on one side. |
Each film-coated tablet contains cobimetinib hemifumarate equivalent to 20 mg cobimetinib.
Excipient with known effect: Each film-coated tablet contains 36 mg lactose monohydrate.
For the full list of excipients, see section 6.1.
Active Ingredient | Description | |
---|---|---|
Cobimetinib |
Cobimetinib is a reversible, selective, allosteric, oral inhibitor that blocks the mitogen-activated protein kinase (MAPK) pathway by targeting the mitogen-activated extracellular signal-regulated kinase (MEK) 1 and MEK 2 which results in inhibition of phosphorylation of the extracellular signal-regulated kinase (ERK) 1 and ERK 2. Therefore, cobimetinib blocks the cell proliferation induced by the MAPK pathway through inhibition of the MEK1/2 signalling node. |
List of Excipients |
---|
Tablet core: Lactose monohydrate Film coating: Polyvinyl alcohol |
Transparent PVC/PVDC blisters containing 21 tablets.
Each pack contains 63 tablets.
Roche Registration GmbH, Emil-Barell-Strasse 1, 79639 Grenzach-Wyhlen, Germany
EU/1/15/1048/001
20 November 2015
Drug | Countries | |
---|---|---|
COTELLIC | Austria, Australia, Brazil, Canada, Cyprus, Ecuador, Estonia, Spain, France, Hong Kong, Croatia, Ireland, Israel, Lithuania, Netherlands, New Zealand, Poland, Singapore, Turkey, United Kingdom, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.